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Abstract
Liver ischemia-reperfusion injury (IRI) is an inherent 
feature of liver surgery and liver transplantation 
in which damage to a hypoxic organ (ischemia) is 
exacerbated following the return of oxygen delivery 
(reperfusion). IRI is a major cause of primary non-
function after transplantation and may lead to graft 
rejection, regardless of immunological considerations. 
The immediate response involves the disruption 
of cellular mitochondrial oxidative phosphorylation 
and the accumulation of metabolic intermediates 
during the ischemic period, and oxidative stress 
during blood flow restoration. Moreover, a complex 
cascade of inflammatory mediators is generated 
during reperfusion, contributing to the extension of 
the damage and finally to organ failure. A variety of 
pharmacological interventions (antioxidants, anti-
cytokines, etc. ) have been proposed to alleviate graft 
injury but their usefulness is limited by the local and 
specific action of the drugs and by their potential 
undesirable toxic effects. Polyethylene glycols (PEGs), 
which are non-toxic water-soluble compounds approved 
by the FDA, have been widely used as a vehicle or a 
base in food, cosmetics and pharmaceuticals, and also 
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(cold storage), and rewarming (graft washout) before 
transplant (reperfusion). The cumulative injuries due 
to each step are determinant for the successful graft 
outcome after transplantation but the most significant 
lesions occur during cold ischemia, graft rewarming and 
normothemic reperfusion after transplantation.
At the cellular level, prolonged ischemia leads to 
ATP breakdown and provokes the accumulation of 
hypoxanthine, mitochondrial de-energization and ionic 
alterations which finally lead to liver cell necrosis. 
Upon oxygenation during reperfusion, reactive oxygen 
species (ROS) generation by uncoupled mitochondria 
promotes oxidative stress and a complex cascade 
of inflammatory mediators (nitric oxide, cytokines, 
adhesion molecules, chemokines, etc.) which all 
contribute to the spread of the damage and finally to 
cell death[4].
Because of the range of mechanisms involved in 
hepatic IRI, the choice of preventive or therapeutic 
strategies is very difficult[5]. Pharmacological strategies 
for preventing IRI focus on the use of specific agents, 
but the benefits of these drugs are limited because of 
their local actions, side effects and potential toxicity. 
In this situation, there is a clear need to test the use 
of non-toxic, water-soluble and protective agents 
for tissues such as PEGs as “preconditioning agents” 
for preventing IRI and also as potential targets for 
therapeutic interventions in organ transplantation. 
This review is an update of the most significant 
advances in the use of polyethylene glycols (PEGs) as 
therapeutic tools for protecting the liver against IRI, 
placing specific emphasis on future perspectives in 
liver graft preservation and transplantation.
PEGS: CHEMICAL STRUCTURE AND 
MEDICAL USE
PEGs are non-immunogenic, non-toxic and water-
soluble polymers which show no electric charge and no 
affinity for any specific organ. They are composed of 
repeating units of ethylene glycol which form polymers 
with a linear shape of different molecular weight[6-9]. 
PEGs with different shapes can be obtained by using 
different initiator molecules during the polymerization 
reaction (e.g., hexa-glycerin instead of methanol to 
form a tri PEG) or by joining different linear PEGs to 
create different structures, as shown in Figure 1.
PEGs are negligibly metabolized in vivo and are 
mainly unaltered when eliminated from the body 
either by the kidneys (for PEGs < 30 kDa, slowly 
for 30 kDa < PEGs < 40 kDa) or in the faeces (for 
PEGs > 20 kDa)[10]. PEGs are generally considered to 
have low toxicity via all routes of administration, as 
demonstrated by tests in many animals[11]. Due to their 
high flexibility, hydrophilicity, and the large number 
of water molecules coordinated by their chains, PEGs 
present a greater hydrodynamic volume than would be 
expected from their molecular weight, and they show 
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as adjuvants for ameliorating drug pharmacokinetics. 
Some PEGs are also currently used as additives in 
organ preservation solutions prior to transplantation in 
order to limit the damage associated with cold ischemia 
reperfusion. More recently, the administration of PEGs 
of different molecular weights by intravenous injection 
has emerged as a new therapeutic tool to protect liver 
grafts from IRI. In this review, we summarize the 
current knowledge concerning the use of PEGs as a 
useful target for limiting liver IRI. 
Key words: Ischemia reperfusion injury; Polyethylene 
glycol; Liver preconditioning; Liver transplantation; 
UW solution; IGL-1 solution; SCOT solution; PEG rinse 
solution; Machine perfusion
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Core tip: Pharmacological treatments for preventing 
liver ischemia reperfusion injury are limited, due to the 
complex pathophysiology of this condition. The drugs 
currently used for preventing ischemia-reperfusion 
injury (IRI) all have local and specific activity with 
potentially damaging side effects. This review focuses 
on the current understanding of polyethylene glycols, 
which are non-toxic polymers, as new emerging agents 
for limiting liver IRI, and proposes directions for future 
investigations. 
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INTRODUCTION
It is well known that the interruption of blood to an 
organ (ischemia) and its subsequent restoration 
(reperfusion) leads to irreversible damage which 
is termed ischemia reperfusion injury (IRI). IRI is 
inherent to liver surgical procedures such as hepatic 
resection and liver transplantation[1-3]. During liver 
resections, the damage is commonly a consequence 
of the vascular occlusion of the liver hilum (Pringle’
s maneuver) under normothermic conditions[1]. In 
the case of transplantation, the damage is sustained 
during cold storage of the liver graft (at 4 ℃) in 
preservation solution following explantation from the 
donor, and during subsequent warm reperfusion and 
implantation into the recipient[4].
There are several steps between organ recovery and 
transplantation that can exacerbate the damage to the 
graft. The most important are organ procurement (pre-
preservation), conservation in preservation solution 
high protein-rejecting properties[12]. 
PEGs have an apparent molecular weight which, 
depending on the molecular weight of the polymer, 
can be 5-10 times higher than a corresponding 
soluble protein of similar molecular mass, as shown 
by gel permeation chromatography[13]. The Food 
and Drug Administration (FDA) has approved the 
use of PEGs as a vehicle or a base in food, cosmetics 
and pharmaceuticals, including injectable and bowel 
solutions[14,15]. For example, low molecular weight PEGs 
are widely used as the basis of a number of laxatives 
and soft capsules, and high molecular weight PEGs 
have been used as components in organ preservation 
solutions to attenuate injury from cold perfusion in 
animal organs such as pancreas[16], small bowel[17], 
kidney[18] and liver[19]. In addition, the attachment of PEG 
(PEGylation) to drugs, peptides, proteins, nanoparticles, 
micelles, and liposomes is spreading as a technology 
for enhancing the bioavailability, stability, safety, and 
efficacy of a wide range of therapeutic agents[20,21]. 
Examples include PEGylated interferon alpha, which is 
used to treat hepatitis C[22], or PEGylated antihuman 
TNF-alpha for rheumatoid arthritis[23]. 
PEG STRATEGIES TO PREVENT 
ISCHEMIA-REPERFUSION INJURY: AN 
APPROACH TO THE LIVER
The use of PEGs to minimize the deleterious effects of 
IRI has not been studied in depth. However, PEGs have 
been shown to be effective in cell protection against 
hypoxia/oxygenation, as additives in preservation and 
perfusion solutions for organ transplantation and, more 
3 June 28, 2016|Volume 22|Issue 24|WJG|www.wjgnet.com
Linear PEG diol
Linear methoxy PEG
Branched PEG
Star PEG
Figure 1  Schematic composition of linear, branched and star polyethylene glycols. Polyethylene glycols (PEGs) is synthesized by a process of linking repeating 
units of ethylene glycol. The reaction gives products with one or two end chain hydroxyl groups termed methoxy-PEG or diol-PEG, respectively. Then, the linear 
PEG with branches at irregular intervals along the polymer chain forms branched PEGs. Star-shaped PEGs are the simplest class of branched PEGs with a general 
structure consisting of several (more than three) linear chains connected to a central core.
an adequate hepatic revascularization after transplan-
tation. Moreover, the NO generated may act as a 
suitable scavenger for preventing the impairment of 
lipid peroxidation in fatty livers against reperfusion[36].
It has also been demonstrated that PEG interferes 
with the coagulation system and reduces platelet 
adhesion in vitro and in vivo[37,38] by forming a 
molecular barrier on the glycocalyx. This PEG barrier 
prevents acute platelet deposition on damaged 
arteries. When a relatively low molecular weight PEG 
(< 10 kDa) was conjugated to pericardium, it reduced 
the deposits of calcium and decreased platelet and 
leukocyte surface attachment[39,40]. Therefore, the 
conjugation of PEG to the surface of endothelial cells 
seemed to reduce inflammation and control water 
content. Longer PEG chains, such as that of PEG35, 
might be expected to interact with the surface of 
endothelial cells of blood vessels and/or remain in the 
interstitial fluid of transplanted liver, thus promoting 
the above mentioned beneficial effects even after the 
washout of the organ graft.
The presence of PEG35 in IGL-1 solution also 
promotes the activation of several protective cell 
signaling pathways during liver cold storage, as a self-
response of the organ to oxygen deprivation. This 
leads to the induction of cytoprotective factors such as 
adenosine monophosphate protein kinase (AMPK), an 
enzyme which is involved in the glucose metabolism 
breakdown and modulates the energy balance towards 
an energy preserving state. PEG35 also activates 
other protective factors associated with the deprivation 
of oxygen supply to the organ such as the hypoxia 
inducible factor HIF alpha[41]. 
PEG in perfusion solutions (graft washout and machine 
perfusion)
Rinse solutions help to wash the liver graft preserved 
in organ preservation solutions by avoiding air 
emboli and the secondary effects of the remnants of 
preservation solution, such as the excessively high 
concentration of intravascular potassium and metabolic 
waste during cold storage[42,43]. Although there is no 
consensus among physicians on how the graft flushes 
should be carried out, the most widely used solutions 
are Ringer Lactate and 5% human albumin[42]. 
PEG35 is a suitable additive in rinse solution for 
an efficient liver graft washout, and also ensures 
additional protection against reperfusion injury[44]. 
Protective mechanisms induced by PEG35 against liver 
reperfusion injury mainly involve the preservation of 
liver mitochondrial status[44], as shown in Figure 2. 
Rhodamine 123 cell viability marker (in green) 
shows the preserved membrane potential of liver 
mitochondria in liver grafts preserved in UW and 
then rinsed with PEG35 solution when compared to 
livers rinsed with Ringer lactate. In this case, Evans 
Blue labeling (in red) shows the albumin content 
and the disrupted mitochondrial membranes. Thus, 
recently, as “preconditioning agents” for preventing 
IRI in heart and liver. As a result, PEGs may offer new 
therapeutic strategies for applications in clinical liver 
surgery and transplantation, as indicated below. 
PEG and cryopreservation (“supercooling”)
Current technologies can preserve livers outside 
the body for about 12 h using a combination of 
cold temperatures and a preservation solution. This 
has helped increase the number of successful liver 
transplants, but extending the time a liver can survive 
outside the body even further would provide many 
extra benefits. 
The presence of PEGs has been shown to be deter-
minant for hepatocyte preservation in hypothermic 
conditions[24-26]. The addition of PEG8 to the preservation 
solution suppressed cell swelling in cultured hepa-
tocytes, keeping them relatively well-preserved and 
restoring membrane integrity[24-26]. This is consistent 
with the further development of a slow-cooling method 
that first chills rat livers at 4 ℃ and then drops the 
temperature to below freezing (named “supercooling”), 
allowing them to be stored in a “supercooled” but non-
frozen state[27]. In this connection, a recent study by 
Berendsen et al[28] presented a method for extended 
liver storage combining supercooling and machine 
perfusion. An essential step in this method was the 
addition of PEG35 to the preservation solution. Similar 
results were found by the same researchers with 
“supercooled” hepatocytes: this addition of 5% PEG35 
to the storage solution prevented cold-induced lipid 
peroxidation and maintained hepatocyte viability and 
functionality during supercooling[25-27]. 
PEGs in organ preservation solutions 
The cold static preservation of solid organs using 
preservation solutions is the gold standard in clinical 
organ transplantation today. PEG35 and PEG20 have 
been used as oncotic agents in IGL-1 and SCOT 20 
preservation solutions respectively to prevent cell 
swelling[29-32]. The presence of PEG35 in IGL-1 makes 
this solution a good alternative to UW solution (the 
standard goal for liver transplantation), especially 
in the presence of moderate to severe hepatic stea-
tosis[33,34]. PEG20 is the basic component of the SCOT 
solution, which furthermore contains low K+/high Na+ 
concentrations. PEG20 at 15 g/L has been found to 
reduce alloantigen recognition after liver reperfusion 
in comparison to UW solution[35]. However, the use of 
this PEG20 in preservation solutions has not shown a 
greater benefit than PEG35[35].
PEG35 (at 1 g/L) plays a key role in reducing 
the higher vulnerability of fatty livers to IRI[33]. This 
is mainly due to the production of nitric oxide (NO), 
whose vasodilatory properties contribute to coun-
teracting the exacerbated alterations of microcirculation 
in steatotic livers due to the accumulation of fat in 
the sinusoids, which makes it more difficult to obtain 
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PEG35 preserves the cytoskeleton structure and cell 
morphology against the effects of IRI[44,45]. 
Static cold preservation remains the gold standard, 
but the growing needs of liver transplantation oblige 
physicians to use machine perfusion (MP) techniques 
in different temperature conditions: hypothermia 
(HMP), normothermia (NMP) and subnormothermia 
(SNMP) for graft preservation purposes[46-48]. The use 
of PEG in MP solutions is very limited in contrast to UW-
gluconate and KPS solutions[46-48]. Bessems et al[49,50] 
have shown that substitution of hydroxyethyl starch 
by PEG in Polysol perfusion solution achieved equal or 
better function and less damage in rat liver after 24 h 
of HMP, and that this Polysol-PEG solution was more 
efficient than UW-Gluconate perfusion solution[49,50]. In 
rat steatotic livers, cold storage using Polysol resulted 
in significantly better integrity and functions of the 
liver[51] and thus improved the preservation quality 
of partial liver transplantation[52]. More recently, it 
was shown that addition of PEG35 to SNMP at 5 g/L 
using the “supercooling” technique was necessary 
to achieve successful liver transplantation after six 
days’ preservation[28,53]. Thus, PEG contributes to the 
rapid extension of cooling and the lower temperatures 
attained also contributed to preserving the membrane 
and cytoskeletal structure of hepatocytes during HMP[25]. 
PEGs as “preconditioning” agents for IRI prevention
Recent investigations in the heart have found that high 
molecular weight PEG (15-20 kilo-daltons) protected 
cardiac myocytes from hypoxia reoxygenation[54]. More 
recently, these cardioprotective benefits for PEG 15-20 
were observed when it was administered just before 
reperfusion[55]. 
With this in mind, our group explored the benefits 
of using PEG35 to limit IRI in different experimental 
models of cold ischemia and warm ischemia reper-
fusion in rats[56,57]. Intravenous administration of 
PEG35 to rats before the induction of cold ischemia-
reperfusion insult (a single 10 mg/kg dose) protected 
fatty livers from the lesions associated with IRI[56]. The 
prevention of liver damage was accompanied by a 
high protection of liver cytoskeleton and mitochondria, 
which was concomitant with increased phosphorylation 
of pro-survival protein kinase b (AKT) and the 
activation of cyto-protective factors such as e-NOS and 
AMPK respectively[56]. 
These investigations reveal that in vivo PEGs 
improve the initial conditions of organs against the 
cold ischemia reperfusion insult. This PEG strategy 
can be considered as a useful tool for multi-organ 
preconditioning before organ recovery and then static 
cold storage/machine perfusion preservation. 
These protective mechanisms of PEG were also 
corroborated in a warm ischemia-reperfusion model 
in the rat[57]. Intravenous administration of PEG35 at 
10 mg/kg was protective against IRI. In this case, 
PEG35 not only prevented mitochondria damage, but 
also promoted the activation of prosurvival pathways 
(AKT, AMPK), and reinforced the cytoskeleton structure 
and preservation of the hepatocytes’ morphological 
features[44,56]. However, the precise mechanisms by 
which PEGs interact with the cytoskeleton remains to 
be elucidated. 
FUTURE PERSPECTIVES
Many studies have been designed to prevent 
mitochondrial dysfunction and to increase endothelial 
NO generation as a tool for favoring a rapid recovery 
of liver graft viability after reperfusion. The use of new 
NO-releasing molecules covalently linked to PEG, as 
oncotic agents for fatty liver preservation, could help 
to prevent exacerbated microcirculation in steatotic 
liver grafts. This practice has been extended to the 
pharmacological preconditioning of fatty livers, with 
very promising results (unpublished data). 
Moreover, the use of another alternative molecule 
similar to butanediol mononitrate, conjugated to 
the carboxylic groups of PEG derivatives by an ester 
linkage, may provide a new kind of PEG derivative 
obtained by preparation of PEG-dendron polymers. 
This may be useful for defining new PEG molecules for 
supercooling purposes either in combination with MP 
or not. 
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PEG35
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Figure 2  PEG35 preserves liver graft function. Confocal microscopy 
images showing green fluorescence of rhodamine 123 cell viability 
marker. Liver grafts were better preserved when they were rinsed with a 
solution containing PEG35 (left) rather than Ringer lactate solution (right).
On the other hand, given the potential of PEGs as 
therapeutic targets for liver protection against IRI, it 
will be important to identify new PEG derivatives for 
use in liver transplantation as preconditioning agents. 
PEG treatment in donors and during reperfusion 
could minimize the deleterious effects of IRI, such as 
oxidative stress, cytoskeleton disruption and apoptosis. 
Moreover, in reduced orthotopic liver transplantation 
(ROLT), the prophylactic administration of PEG to 
donor or/and recipient could contribute to a better liver 
regeneration of the implanted reduced graft and thus 
contribute to preventing the small-for-size syndrome 
present in living-living donor transplantation. In this 
particular case, the use of new derivatives based on 
growth factors releasing molecules covalently linked 
to PEG could offer potential advantages for rapid liver 
regeneration. Hepatic Growth Factor may be a suitable 
candidate (59). The benefits and perspectives of PEGs 
for limiting liver IRI are summarized in Figure 3.
CONCLUSION
The use of PEG may improve the initial conditions of 
organs available for transplantation, especially in the 
case of the most vulnerable ones such as steatotic 
livers. PEG is a very promising tool for limiting IRI in 
liver surgery (hepatectomy and transplantation) but 
further investigation in clinical trials is needed.
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